Clinical Trial Update: The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention [Phase 2]

View source ↗

Summary

This is a Phase 2 trial comparing otamixaban to heparin in patients undergoing non-urgent percutaneous coronary intervention, and the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Heparin (unfractionated heparin)
• Otamixaban (otamixaban)

Snippet

Sponsor: Sanofi | Conditions: Angioplasty, Transluminal, Percutaneous Coronary | Phase 2 | Status: COMPLETED